Production (Stage)
CARGO Therapeutics, Inc.
CRGX
$4.37
-$0.05-1.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.70% | 34.74% | 72.58% | 206.70% | 283.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.28% | 43.42% | 64.09% | 177.13% | 167.63% |
| Operating Income | -3.28% | -43.42% | -64.09% | -177.13% | -167.63% |
| Income Before Tax | -135.96% | -41.64% | -18.15% | -148.42% | -180.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -135.96% | -41.64% | -18.15% | -148.42% | -180.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -135.96% | -41.64% | -18.15% | -148.42% | -180.94% |
| EBIT | -3.28% | -43.42% | -64.09% | -177.13% | -167.63% |
| EBITDA | -3.03% | -43.36% | -64.25% | -178.16% | -167.75% |
| EPS Basic | -102.15% | 36.15% | 98.14% | 96.15% | 95.91% |
| Normalized Basic EPS | 8.57% | 36.14% | 98.14% | 96.15% | 95.00% |
| EPS Diluted | -102.15% | 36.15% | 98.14% | 96.15% | 95.91% |
| Normalized Diluted EPS | 8.57% | 36.14% | 98.14% | 96.15% | 95.00% |
| Average Basic Shares Outstanding | 16.72% | 121.82% | 6,264.57% | 6,347.17% | 6,770.44% |
| Average Diluted Shares Outstanding | 16.72% | 121.82% | 6,264.57% | 6,347.17% | 6,770.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |